CEO Executive AssistantMarket development in the pharmaceutical industry encompasses the activities that create the conditions for commercial success before and after product launch: disease awareness education, healthcare provider education, guideline development support, patient advocacy engagement, health systems research, and access infrastructure development. These activities often take years to yield commercial returns and require sustained professional management that extends well beyond what any CEO can provide personally.
Pharma CEOs who remain too involved in market development activities, reviewing every disease awareness campaign, attending every patient advocacy meeting, or personally managing relationships with medical specialty societies, are misallocating their time and limiting the scale of what a professional market development function can accomplish.
This guide establishes the delegation structure that enables professional, scaled market development while keeping the CEO engaged at the strategic level.
The Market Development Function and Its Leadership
Market development sits at the intersection of Medical Affairs, Commercial, and sometimes Government Affairs. Depending on the company’s structure, it may be a standalone function, a subset of Medical Affairs, or integrated within the commercial organization. Regardless of structure, it needs a designated leader with clear accountability.
The Head of Market Development (or equivalent title) owns: disease awareness programs, healthcare provider education strategy, patient advocacy relationship management, real-world evidence strategy for market development purposes, health systems and payer education, and professional society engagement. This person should have a clear mandate and defined decision authority.
The CEO’s role in market development is to: endorse the market development strategy, ensure adequate investment in market development programs, participate in the most significant external stakeholder engagements where CEO presence adds organizational credibility, and review market development outcomes as part of the regular commercial strategy review.
Disease Awareness Delegation
Disease awareness programs, which educate patients, caregivers, and healthcare providers about conditions that company products address, are complex, multi-channel communication programs with significant compliance requirements. Managing these programs operationally is not a CEO function.
The Head of Market Development, in coordination with Medical Affairs and the compliance function, owns disease awareness program strategy and execution. This includes: identifying the key disease awareness gaps, designing programs that address those gaps within compliance-approved parameters, managing program agencies and vendors, and measuring program effectiveness.
The CEO’s disease awareness role is limited to: approving the overall disease awareness strategy and budget as part of the annual planning process, participating in high-visibility awareness moments such as disease awareness months where CEO visibility signals organizational commitment, and ensuring investor communications about market development investments are accurate and appropriately framed.
Compliance with FDA regulations on disease awareness communications, including the distinction between branded promotion and unbranded awareness, is a Medical Affairs and compliance responsibility. The CEO should understand this framework at a general level but should not be reviewing individual program materials for compliance.
Patient Advocacy Delegation
Patient advocacy organizations are important stakeholders in pharmaceutical market development: they influence treatment guidelines, shape patient and caregiver perceptions, engage with regulatory agencies, and advocate for insurance coverage. Managing these relationships professionally requires dedicated attention.
The Head of Patient Advocacy (sometimes within Medical Affairs) owns the patient advocacy relationship portfolio. This includes: identifying relevant patient advocacy organizations, developing relationship strategies for key organizations, managing financial support within compliance-approved frameworks, and coordinating patient advocacy engagement with Medical Affairs, Commercial, and Government Affairs.
The CEO’s patient advocacy role is to participate in the most significant strategic relationship moments: meeting with the leadership of major disease-specific patient advocacy organizations, speaking at flagship patient advocacy events where CEO participation is expected, and representing the company’s patient commitment in investor and media contexts.
These CEO-level advocacy engagements should be planned and coordinated by the Head of Patient Advocacy, not managed ad hoc by the CEO. Define an annual patient advocacy calendar for the CEO that includes the two to four engagements per year where CEO presence is genuinely strategic.
Medical Society and KOL Relationship Delegation
Professional medical societies and Key Opinion Leaders (KOLs) are critical influencers of treatment practice in pharmaceutical markets. Managing these relationships at scale requires a professional Medical Affairs function with the expertise and time to invest in sustained relationship development.
The Medical Affairs function, under the CMO’s leadership, should own the KOL relationship management program: identifying and tiering KOLs, developing relationship strategies for key KOLs, managing advisory board programs, coordinating speaker and publication activities within compliance-approved frameworks, and monitoring KOL sentiment about the company’s therapeutic area.
The CEO’s KOL engagement is limited to a small number of the most influential thought leaders in the company’s key therapeutic areas. These CEO-level KOL relationships should be managed with the same discipline as major donor relationships in fundraising: defined touchpoints, coordinated strategy, and clear purpose for each engagement. The Medical Affairs function coordinates the CEO’s KOL engagement calendar and ensures CEO interactions with KOLs are appropriately documented.
For a comprehensive view of how market development delegation connects to the clinical and regulatory functions, see pharma CEO clinical ops, which covers how clinical operations and medical affairs work together to support commercial market development.
Health Economics and Outcomes Research Delegation
Health economics and outcomes research (HEOR) is increasingly important for pharmaceutical market development: demonstrating the value of new therapies to payers, health technology assessment bodies, and healthcare systems requires rigorous economic and outcomes data. Managing the HEOR function is a specialized scientific and commercial responsibility.
The Head of HEOR (typically within Market Access or Medical Affairs) should own the HEOR strategy and evidence generation plan. This includes: identifying the key value evidence gaps for each product, designing and managing real-world evidence studies and economic models, coordinating HEOR publication strategy, and supporting payer and health system engagement with HEOR data.
The CEO’s HEOR engagement is limited to: approving the annual HEOR investment as part of the overall R&D and commercial budget, understanding the HEOR narrative at a strategic level for investor communications, and ensuring HEOR evidence is appropriately integrated into market access and commercial strategy.
Delegating Health Systems Engagement
Large health systems, integrated delivery networks, and accountable care organizations are increasingly important customers and market development partners for pharmaceutical companies. Managing these relationships professionally requires dedicated account management capabilities.
Health systems engagement should be owned by a Health Systems function within the commercial organization, typically with Key Account Managers or Regional Medical Science Liaisons managing individual health system relationships. The CEO’s health systems engagement is limited to: meeting with C-suite leaders of the most strategically important health systems, participating in joint venture or partnership discussions with health systems above a defined strategic threshold, and representing the company in forums where health system and pharmaceutical industry relationships are discussed at a policy level.
According to Forbes analysis of pharmaceutical market development trends, companies that invest in professional market development capabilities with appropriate executive strategic engagement build more sustainable commercial positions than those relying on product-only commercial strategies. The delegation structure that enables this capability investment is exactly what this guide describes.
Measuring Market Development Delegation Effectiveness
The effectiveness of market development delegation should be measured by outcomes, not activity. Key metrics for the CEO’s market development oversight include:
- Disease awareness levels in target patient populations (measured through market research)
- Healthcare provider prescribing readiness for new therapeutic approaches
- Patient advocacy organization sentiment and engagement quality
- KOL endorsement and guideline inclusion status for key clinical practices
- Health system formulary and pathway inclusion rates
These metrics, reviewed quarterly as part of the commercial strategy review, give the CEO strategic visibility into market development effectiveness without requiring operational involvement in program management.
See pharma CEO delegation guide for a comprehensive framework connecting market development delegation to the overall pharma CEO delegation strategy, including how to structure accountability for market development outcomes within the commercial leadership team.
When market development is delegated effectively, the CEO sees a professional function operating at scale, with consistent engagement across patient advocacy, medical education, and health systems that no CEO could personally sustain. This is the definition of organizational leverage: the CEO’s strategic vision, amplified by a capable team that executes it systematically and professionally.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.